Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Ubiquitin-Specific Peptidase 22 Target Validation.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for USP22 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | USP22 Recombinant Protein (Full-Length / Catalytic Domain) High purity (>95%), Endotoxin controlled. Sequence Verified by Mass Spectrometry. Suitable for biochemical assays. |
View USP22 Products |
| Gene Delivery | USP22 Promise-ORF / Lentivirus Full-length human USP22 ORF for stable cell line generation and overexpression validation. |
View USP22 Products |
| Benchmark Ab | Anti-USP22 Recombinant Antibody High-affinity positive control for Western Blot, IHC, and immunoprecipitation assays. |
View USP22 Products |
| Validator | USP22 siRNA Set Target-specific gene knockdown validation to confirm target-specific phenotype changes. |
View USP22 Products |
| Related Target A | SIRT1 USP22 deubiquitinates and stabilizes SIRT1, preventing its proteasomal degradation and promoting cell survival. |
View SIRT1 Products |
| Related Target B | MYC USP22 acts as a positive regulator of MYC karyophilic stability and transcriptional activity in aggressive tumors. |
View MYC Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily counter-screening (selectivity over other DUBs) | USP subfamily panel proteins (USP7, USP14, USP28) strictly sequence verified and purity checked via SDS-PAGE. |
| Assay sensitivity and enzyme stability | HEK293 or insect-cell expressed proteins preserving native post-translational modifications and tertiary conformation. |
| Lack of Controls | Sequence-derived benchmark antibodies available for robust assay calibration. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for target-specific knockdown verification in cell-based assays. |
Live USP22 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for USP22 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum deubiquitinating enzyme (DUB) inhibitors to highly selective small molecules and PROTACs (Proteolysis Targeting Chimeras). As first-generation DUB inhibitors reach preclinical and early clinical milestones, the next wave of R&D is targeting USP22 due to its critical role in the SAGA (Spt-Ada-Gcn5 acetyltransferase) complex and its regulation of cancer stem cell stemness, immune evasion, and therapy resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Ubix Therapeutics, Mission Therapeutics | Oncology (Breast, Colorectal, NSCLC) | Selectivity Assay (Need High-Purity USP22 vs. USP7/USP14 panel) |
| PROTACs / Degraders | Arvinas, Academic Consortia | Refractory / Metastatic Cancers | Ternary Complex Formation (Need biotinylated/tagged USP22 proteins) |
| Combination Therapies | Pfizer, AstraZeneca | Immunotherapy-resistant tumors | Synergy Validation (Need USP22 CRISPR/siRNA and PD-L1 reference lines) |